近日，隨著 “杭州六小龍” 刷屏，新華社、英國《經(jīng)濟學(xué)人》等海內(nèi)外媒體都關(guān)注到坐落在杭州的浙江大學(xué)。“六小龍” 背后，DeepSeek 創(chuàng)始人梁文鋒在浙大信息與電子工程學(xué)院完成本碩學(xué)習(xí)，云深處科技創(chuàng)始人朱秋國畢業(yè)、任教于浙大，群核科技三名創(chuàng)始人中的兩位——黃曉煌、陳航畢業(yè)于浙大竺可楨學(xué)院。

與此同時，基礎(chǔ)科研領(lǐng)域也傳來好消息。具有全球影響力的自然指數(shù)（Nature Index）官網(wǎng)更新最新排名，哈佛大學(xué)位居全球高校第一，浙江大學(xué)位居全球高校第三。（自然指數(shù)是依托于《自然》系列、《科學(xué)》《細(xì)胞》、醫(yī)學(xué)等 145 種全球頂級期刊，統(tǒng)計全球各高校、科研院所（國家）發(fā)表論文數(shù)量的數(shù)據(jù)庫，是國際公認(rèn)的衡量自然科學(xué)領(lǐng)域高質(zhì)量研究產(chǎn)出與合作情況的重要指標(biāo)。）同期，在最新一輪全國重點實驗室重組后，浙江大學(xué)牽頭的實驗室數(shù)量排名全國第二，僅次于清華大學(xué)。

這些在產(chǎn)業(yè)界和基礎(chǔ)研究領(lǐng)域同步取得的成果背后，有哪些驅(qū)動因素？產(chǎn)學(xué)研融合發(fā)展之路在何方？創(chuàng)新創(chuàng)業(yè)如何借力高校科研資源？就上述話題，浙江大學(xué)在上周首辦上市公司企業(yè)家校友交流會，校黨委書記任少波出席活動并發(fā)表講話，晶泰科技聯(lián)合創(chuàng)始人、首席執(zhí)行官馬健博士受邀參與活動，與 30 余名上市公司企業(yè)家校友一起回到母校，共同探討、熱議交流。

浙江大學(xué)黨委書記任少波發(fā)表講話

任少波指出，2025 年會帶來新的機遇和挑戰(zhàn)。一批師生、校友創(chuàng)新創(chuàng)業(yè)的事跡和貢獻，讓全球浙大人自豪、振奮，要從中學(xué)習(xí)和弘揚求是之風(fēng)，堅守本質(zhì)和長期主義，形塑誠勤實真的浙大人特質(zhì)；高舉 “創(chuàng)新浙大” 旗幟，勇于謀劃原創(chuàng)和戰(zhàn)略任務(wù)，組織強大鏈接攜手走向全球前列；擦亮 “創(chuàng)業(yè)浙大” 品牌，提供高品質(zhì)前瞻性交流平臺，讓校友會成為戰(zhàn)略服務(wù)者，在新形勢下創(chuàng)新校友工作模式，共筑校友生態(tài)網(wǎng)絡(luò)。

晶泰科技聯(lián)合創(chuàng)始人、首席執(zhí)行官馬健博士現(xiàn)場發(fā)言

馬健博士于浙江大學(xué)完成本科學(xué)習(xí)并保送直博，理論物理博士畢業(yè)后前往麻省理工學(xué)院繼續(xù)博士后研究。2015 年，馬健博士與溫書豪博士、賴力鵬博士聯(lián)合創(chuàng)立晶泰科技，公司自主研發(fā)了基于量子物理并以人工智能賦能和機器人驅(qū)動的創(chuàng)新研發(fā)平臺，加速新藥研發(fā)、新材料發(fā)現(xiàn)以及化學(xué)自動化，并于 2024 年 6 月在香港交易所主板掛牌上市，成為首家以香港 18C 規(guī)則上市的特專科技企業(yè)。

馬健博士表示，一直以來，晶泰科技都致力于推進基礎(chǔ)科研和前沿技術(shù)的融合創(chuàng)新，面對新一輪科技革命和產(chǎn)業(yè)變革帶來的機遇和挑戰(zhàn)，將依托 AI + 機器人科技平臺型企業(yè)的優(yōu)勢，重點在生物醫(yī)藥、新材料、化學(xué)化工等垂直領(lǐng)域探索開發(fā)超級人工智能。在此過程中，企業(yè)將不斷加強與浙江大學(xué)等基礎(chǔ)科研實力雄厚的高校院所在聯(lián)合技術(shù)攻關(guān)、科研成果轉(zhuǎn)化、創(chuàng)新人才培養(yǎng)等方面的交流與合作，構(gòu)建產(chǎn)學(xué)研聯(lián)合創(chuàng)新共同體，以協(xié)同創(chuàng)新模式，挑戰(zhàn)破解科研難題，共同投身到中國式現(xiàn)代化建設(shè)中，參與新一輪全球科技和產(chǎn)業(yè)競爭。

浙江大學(xué)上市公司企業(yè)家校友交流會全體合影

The post 馬健博士受邀參加浙江大學(xué)上市公司企業(yè)家校友交流會 appeared first on 晶泰科技 XtalPi.

挑戰(zhàn):

• SARM1具顯著的動態(tài)構(gòu)象變化，體外難以穩(wěn)定并捕捉其激活態(tài)構(gòu)象；
• 目前的候選藥物分子主要為競爭性抑制劑，缺乏明確的抑制機制。

目標(biāo):

• 通過晶泰科技AI驅(qū)動的Cryo-EM圖像處理模塊，幫助加速解析抑制劑與SARM1的高分辨率電鏡結(jié)構(gòu)，為理性藥物設(shè)計提供新思路、新方向；
• 進一步揭示該靶點的自抑制態(tài)與激活態(tài)的轉(zhuǎn)換機制，加深對靶點作用機理的理解。

結(jié)構(gòu)解析流程：

解析結(jié)果：

項目小結(jié)：

僅使用200kV電鏡，在8 周內(nèi)成功解析SARM1與抑制劑的2.8 ?結(jié)構(gòu)，這項開創(chuàng)性研究成果揭示了一種小分子抑制劑的競爭性抑制機制。高比例NMN/NAD+誘導(dǎo)激活SARM1，抑制劑在SARM1催化下與NAD+發(fā)生堿基交換反應(yīng)，生成抑制劑-ADPR這一新產(chǎn)物，該產(chǎn)物與SARM1結(jié)合并鎖定其處于激活態(tài)構(gòu)象，封鎖底物NAD+結(jié)合口袋，從而抑制SARM1的NAD+降解活性。該結(jié)果為證實SARM1的激活機制和堿基交換反應(yīng)提供了最直接的結(jié)構(gòu)證據(jù)。

數(shù)據(jù)計算過程中，通過使用 AI 驅(qū)動的圖像處理模塊實現(xiàn)了目標(biāo)顆粒的精確挑選，與經(jīng)典方法相比，在同等算力下，加速整體計算流程并實現(xiàn)更高的分辨率。

同時，首次從分子水平揭示了 SARM1 的激活機制，加深對其如何介導(dǎo)退行性疾病發(fā)生機理的理解。

The post 8周解析SARM1蛋白結(jié)構(gòu) appeared first on 晶泰科技 XtalPi.

Explore Two Case Studies on How XtalPi Leveraged MicroED to Address Different Polymorphism Challenges

Structural elucidation is a critical process in understanding and addressing polymorphism challenges in drug development. Here are two case studies highlighting how our technical team employed MicroED to determine the structures of crystalline samples in just 5 days, providing crucial structural information to tackle complex polymorphism issues.

Case Study 1: Determining Component Ratio in a Non-stoichiometric Co-former System Using MicroED?

XtalPi’s Approach & Findings

• Explained the varying stoichiometric ratios of a monobasic API and methanesulfonic acid in a non-stoichiometric co-former through MicroED-derived crystal structure.
• Revealed that methanesulfonic acids are situated in disordered lattice channels within a complex asymmetric unit that contains 8 APIs and 14 co-formers.

Case Study 2: MicroED Discovered an Unexpected Polymorphism from Samples with Highly Similar XRPD Patterns

XtalPi’s Approach & Findings

• Identified distinct polymorphic structures from two batches of samples with nearly identical XRPD spectra but different analytical profiles.
• Mitigated polymorphism risk by achieving definitive structural assignments using MicroED when single crystals could not be obtained for the samples. 

The post How XtalPi Utilized MicroED to Tackle Different Polymorphism Challenges appeared first on 晶泰科技 XtalPi.

Case Study: Harnessing CSP and MicroED to Determine Remdesivir’s Most Stable Polymorph in Just 33 Days

Accurately identifying the most stable polymorph is essential for successful drug development, especially when facing tight R&D timelines and limited material availability.?Faced with two similar Remdesivir anhydrates, our team utilized an integrated?experimental?and AI-driven computational approach to quickly pinpoint the most stable polymorph across varying temperatures, ensuring a reliable drug product development.?

Here’s how we delivered results 2x faster than standard polymorph research:

• Utilized?MicroED?to determine crystal structures of Form II and, for the first time, of Form IV to explain their similar XRPD patterns and properties.?
• Leveraged AI-powered?Crystal Structure Prediction (CSP)?platform to predict and recommend Form II as the most stable anhydrate at room and high temperatures, well ahead of traditional timelines.?

The post Accelerated Identification of the Most Stable Remdesivir Polymorph in 33 Days Using an Integrated Experimental and Computational Approach appeared first on 晶泰科技 XtalPi.

Case Study: How the XtalPi Team Discovered Novel, Non-Covalent, Potent Hits Against GPX4 in 28 Days

GPX4 is a critical enzyme for cellular antioxidant defense, but is a highly challenging target. In this case study, we share the story of how we discovered three novel non-covalent hit compounds with biochemical IC₅₀?< 10μM in just 28 days.

• Using predictive AI models and physics-based computations, we probed key pharmacophores with high accuracy and throughput, even without reference compounds.
• 159 library compounds were proposed and 124 were successfully synthesized using our automation platform.

The post Hit Identification – Novel Hits for GPX4 appeared first on 晶泰科技 XtalPi.

The post Application Note: DEL Screening appeared first on 晶泰科技 XtalPi.

Case Study: How the XtalPi Team Discovered a Selective, Novel Lead Series for Key Cancer Target SMARCA2

Loss-of-function mutations in SMARCA4 occur in various cancers, leading to an increased dependency on the structurally similar SMARCA2 for activity. This makes SMARCA2 an attractive therapeutic target due to its increased importance in cancer cell survival.

However, identifying novel small-molecule SMARCA2-selective inhibitors poses significant challenges. To address this, XtalPi leveraged its advanced AI-powered discovery platform and Cryo-EM technology, opening up new possibilities for targeted cancer treatments.

Our Key Results: 

• Discovered a novel lead series with high efficacy and 20-fold selectivity for SMARCA2 over SMARCA4 in biochemical assays, showcasing strong potential for further development.
• Identified a unique SMARCA2 binding pocket using Cryo-EM at 2.9 ? resolution, offering new insights for the design of selective inhibitors and advancing structure-based drug discovery.
• Achieved 100% library compound synthetic success rate by proprietary synthetic feasibility prediction models.

The post Lead Identification – Discovering Selective Inhibitors Against an Unreported Binding Pocket of SMARCA2 via a Rational Drug Design Approach appeared first on 晶泰科技 XtalPi.